Phase II trial of S-1 in combination with gemcitabine in chemo-naïve patients with locally advanced or metastatic pancreatic cancer
03 medical and health sciences
0302 clinical medicine
3. Good health
DOI:
10.1200/jco.2008.26.15_suppl.15577
Publication Date:
2017-02-24T07:33:44Z
AUTHORS (6)
ABSTRACT
15577 Background: Gemcitabine monotherapy is currently accepted as a standard first-line treatment of unresectable pancreatic cancer. However, the prognosis of patients with unresectable pancreatic...
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (2)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....